Lymph node identification in skin malignancy using indocyanine green transcutaneously study: Study protocol for a diagnostic accuracy study

Ioana Lese, Jonathan Ian Leckenby, Adriano Taddeo, Mihai Constantinescu, Radu Olariu, Ioana Lese, Jonathan Ian Leckenby, Adriano Taddeo, Mihai Constantinescu, Radu Olariu

Abstract

Introduction: The incidence of malignant melanoma has been rising steadily over the past decades and Merkel cell carcinoma is a highly aggressive neuroendocrine skin tumor with a high mortality rate. Sentinel lymph node (SLN) biopsy is a recommended prognostic tool in primary cutaneous malignant melanomas of intermediate thickness and in all clinically node-negative Merkel cell carcinomas. The gold standard method for identification of SLNs is lymphoscintigraphy, which involves radioactive tracers. Indocyanine green-based near-infrared fluorescence imaging (NIRFI) has been also used for intraoperative SLN identification. We aim to evaluate the diagnostic sensitivity of the VisionSense VS3 NIRFI device for SNL identification. This device uses stereoscopic 3D high definition for both fluorescence and visible light imaging. Our hypothesis is that SLNs may be identified transcutaneously using fluorescent dye injections and NIRFI; therefore, obviating the need for lymphoscintigraphy in the future. METHODS AND ANALYSIS:: lymph node identification in skin malignancy using indocyanine green transcutaneously is a prospective diagnostic sensitivity study conducted at the Department of Plastic and Hand Surgery at the University Hospital Berne, Inselspital, Switzerland. The study aims at recruiting 93 patients (start date September 2017) to compare the accuracy of VisionSense VS3 camera at identifying SLNs transcutaneously with the current gold standard, lymphoscintigraphy. Moreover, a secondary objective is to determine if anatomical location of the SLN and patient factors (eg, body mass index, age) have an impact on the ability of VisionSense to detect SLNs when compared with the same gold standard.

Trial registration number: ClinicalTrials.gov NCT03545334.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Timeline of a patient included in the study, including deviations from the standard.

References

    1. Forsea AM, Del Marmol V, de Vries E, et al. Melanoma incidence and mortality in Europe: new estimates, persistent disparities. Br J Dermatol 2012;167:1124–30.
    1. Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 2017;3:524–48.
    1. Dummer R, Siano M, Hunger RE, et al. The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. Swiss Med Wkly 2016;146:w14279.
    1. Allen PJ, Bowne WB, Jaques DP, et al. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol 2005;23:2300–9.
    1. Tello TL, Coggshall K, Yom SS, et al. Merkel cell carcinoma: an update and review: current and future therapy. J Am Acad Dermatol 2018;78:445–54.
    1. Pavri SN, Clune J, Ariyan S, et al. Malignant melanoma: beyond the basics. Plast Reconstr Surg 2016;138:330e–40e.
    1. Gupta SG, Wang LC, Penas PF, et al. Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: the Dana-Farber experience and meta-analysis of the literature. Arch Dermatol 2006;142:685–90.
    1. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:472–92.
    1. Niebling MG, Pleijhuis RG, Bastiaannet E, et al. A systematic review and meta-analyses of sentinel lymph node identification in breast cancer and melanoma, a plea for tracer mapping. Eur J Surg Oncol 2016;42:466–73.
    1. Stratmann SL, McCarty TM, Kuhn JA. Radiation safety with breast sentinel node biopsy. Am J Surg 1999;178:454–7.
    1. El-Desoky A, Seifalian AM, Cope M, et al. Experimental study of liver dysfunction evaluated by direct indocyanine green clearance using near infrared spectroscopy. Br J Surg 1999;86:1005–11.
    1. Benson RC, Kues HA. Fluorescence properties of indocyanine green as related to angiography. Phys Med Biol 1978;23:159–63.
    1. Fujiwara M, Mizukami T, Suzuki A, et al. Sentinel lymph node detection in skin cancer patients using real-time fluorescence navigation with indocyanine green: preliminary experience. J Plast Reconstr Aesthet Surg 2009;62:e373–8.
    1. Fujisawa Y, Nakamura Y, Kawachi Y, et al. A custom-made, low-cost intraoperative fluorescence navigation system with indocyanine green for sentinel lymph node biopsy in skin cancer. Dermatology (Basel, Switzerland) 2011;222:261–8.
    1. Tanaka R, Nakashima K, Fujimoto W. Sentinel lymph node detection in skin cancer using fluorescence navigation with indocyanine green. J Dermatol 2009;36:468–70.
    1. Namikawa K, Tsutsumida A, Tanaka R, et al. Limitation of indocyanine green fluorescence in identifying sentinel lymph node prior to skin incision in cutaneous melanoma. Int J Clin Oncol 2014;19:198–203.
    1. Murawa D, Hirche C, Dresel S, et al. Sentinel lymph node biopsy in breast cancer guided by indocyanine green fluorescence. Br J Surg 2009;96:1289–94.
    1. Cohen JF, Korevaar DA, Altman DG, et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open 2016;6:e012799.
    1. Ahn C. Statistical methods for the estimation of sensitivity and specificity of site-specific diagnostic tests. J Periodontal Res 1997;32:351–4.
    1. Rao JN, Scott AJ. A simple method for the analysis of clustered binary data. Biometrics 1992;48:577–85.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться